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Abstract The serine/threonine protein kinase Akt is a key
molecule in the phosphatidyl inositol 3-kinase pathway that
is often overactivated in human cancers. Three Akt iso-
forms (Akt1, Akt2, Akt3) have been identified in human
cells and they show different distribution and have non-
redundant functions. The aim of this study was to determine
whether the expression, phosphorylation, and localization
of Akt1 isoform in human thyroid malignant lesions are
different from those in benign lesions. Nuclear and
cytoplasmic fractions were isolated from tissue samples
and Western blot method was used to detect Akt1 presence
in both cellular fractions. Akt1 expression was also
assessed by ELISA method. To estimate Akt1 phosphory-
lation, kinase was immunoprecipitated from cell lysates and
tested with anti-phospho-Akt antibodies. The Akt1 expres-
sion in majority of thyroid cancer samples was significantly
higher than in benign lesions (p<0.05). Akt1 both in
differentiated cancers (follicular and papillary) and benign
lesions was localized mainly in cytoplasmic fraction. In two
of three anaplastic cancer samples Akt1 was predominantly
localized in nucleus. The ratio of phosphorylated Akt1 to
total Akt1 was lower in cancers than in non-neoplastic
lesions and adenomas. Thus, although Akt1 seems to be
overexpressed in thyroid neoplasms, its high phosphoryla-
tion is not characteristic for thyroid cancers.
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Introduction
Follicular epithelial cell-derived thyroid tumors are the
most common endocrine neoplasms and can be classified
into thyroid adenoma (ADE), papillary thyroid cancer
(PTC), follicular thyroid cancer (FTC), and anaplastic
thyroid cancer (ATC). The papillary and follicular thyroid
carcinomas constitute the majority of thyroid carcinomas
and belong to well-differentiated thyroid carcinomas. ATC
is undifferentiated and is the most aggressive thyroid cancer
that may arise de novo or from one of the differentiated
cancers [1]. The pathogenesis and progression of thyroid
neoplasms are characterized by the alteration of multiple
signaling pathways and by abnormalities in a variety of
tumor suppressor genes and cell cycle proteins [2].
Increased activity of phosphatidyl inositol 3-kinase
(PI3K)/Akt pathway was frequently observed in thyroid
cancers [3]. The activation of the PI3K/Akt protein kinase
pathway appears to play an important role both in the
development of thyroid tumors and in their progression [3].
It is suggested that oncogenic activation of the PI3K/Akt
pathway drives transformation of adenoma to FTC and then
to ATC. Moreover, PTC develops de novo after activation
of MAP kinase pathway by oncogenic genetic alterations,
such as BRAF mutation, and its transformation to ATC may
be facilitated by PI3K/AKT pathway [1].
Akt is a serine/threonine protein kinase activated by a
variety of growth factors, including insulin, insulin-like
growth factor-I, and epidermal growth factor, via the
phosphatidylinositol 3-kinase pathway and plays a role in
tumorigenesis by inhibiting apoptosis and mediating cell
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phosphorylation at Thr308 and Ser473. Phospho-Akt (p-
Akt) protects cells from apoptosis by inactivation of
apoptotic cascade components, such as proapoptotic Bad,
caspase-9, and members of the forkhead transcription factor
family. Furthermore, Akt has been implicated in regulating
metastasis, which is an important process in cancer
development [4, 5].
Three Akt isoforms (Akt1, Akt2, and Akt3) have been
identified in mammalian cells and each is transcribed from
separate genes. The Akt isoforms show significant homol-
ogy to each other but they have different distribution. In
physiological conditions, Akt1 and Akt2 seem to be
ubiquitously expressed, whereas Akt3 has more restricted
distribution, with predominance toward the heart, kidney,
brain, testes, lung, and skeletal muscle [6]. Murine gene
deletion models demonstrate that Akt isoforms have non-
redundant functions. Whereas Akt1 null mice have growth
retardation, mice lacking Akt2 show abnormal glucose
homeostasis and diabetic phenotype and mice lacking Akt3
have reduced brain size [7–9].
In the normal thyroid, all three Akt isoforms are expressed
but Akt1 is the predominant isoform at both mRNA and
protein levels [2]. Akt1 seems to be also a principal
overexpressed and overactivated isoform of Akt in thyroid
cancers compared to normal tissue. It is suggested that
activation of this isoform is associated with tumor invasion
and metastasis in follicular and papillary cancers [10, 11].
The aim of this study was to determine whether the
expression, phosphorylation, and localization of Akt1 in
human thyroid malignant lesions are different from those in
benign tumors and non-neoplastic tissues.
Materials and Methods
Surgical Specimens
Surgical speciments were obtained from 45 patients (10
males and 35 females), who underwent surgery for nodular
thyroid disease. Thyroid specimens from patients were
rapidly frozen and stored at −80°C. All tissues were
carefully check and evaluated by an experienced patholo-
gists. The studies were preformed on 16 specimens of non-
neoplastic lesions (nodular goiters), 6 cases of follicular
adenomas, 4 follicular, 16 papillary, and 3 anaplastic
carcinomas.
Isolation of Cytoplasmic and Nuclear Fractions
Thawed tissue samples were homogenized for 3 min in
Potter's homogenizer in 10 volumes of 0.25 M sucrose
containing 5 mM MgCl2, 0.8 mM KH2PO4 (pH 6.8), 0.5%
Triton X-100, and protease inhibitors. The homogenates
were centrifuged at 800×g for 7 min. The crude nuclear
pellet was suspended in 10 volumes of 2.2 M sucrose,
5 mM MgCl2 and centrifuged at 40,000×g for 45 min. The
purity and integrity of the nuclei were checked by phase-
contrast light microscopy. The supernatant obtained after
separation of nuclei from homogenate of thyroid patholog-
ical specimens was centrifuged at 2,500×g for 10 min to
pellet any remaining nuclei. The supernatant obtained after
this centrifugation was considered as cytoplasmic fraction.
The cytoplasmic and nuclear proteins samples were mixed
with solubilizing buffer and heated in a boiling water bath
for 5 min and run on SDS-PAGE.
Enzyme Linked Immunosorbent Assay
For semi-quantitative analysis of Akt1 expression in
cytoplasmic fractions, enzyme linked immunosorbent assay
(ELISA) method was used. Samples of cytoplasmic fraction
to be assayed for the presence of Akt1 were diluted to a
final concentration of 2.5 μg/ml in 0.1 M carbonate buffer,
pH 9.8. The diluted samples (100 μl) were added to the
wells of the 96-well microtiter polystyrene plates (Bio-Rad,
Hercules, USA). The attachment of proteins to the wells
was effected by overnight incubation at 4°C and then the
plates were washed three times with TBS buffer (Tris-
buffered saline) containing 0.05% Tween 20 (TTBS). The
nonspecific binding sites were blocked by the addition of
200 μl of 2% BSA in TTBS buffer to each well, followed
by incubation for 1 h at room temperature. Microtiter plates
were again washed three times with TTBS and incubated
during2ha troom temperature with 100 μl per well of the
mouse monoclonal anti-Akt1 antibody (Santa Cruz Bio-
technology, Santa Cruz, CA, USA) diluted in TTBS
1:1,000. After washing the plates three times with TTBS
buffer, the goat anti-mouse antibodies conjugated with
horseradish peroxidase (100 μl per well) (Santa Cruz
Biotechnology) were added (dilution of antibodies
1:5,000). The plates were incubated for 1 h at room
temperature and washed with three changes of TTBS. The
color reaction was developed by adding 100 μl per well of
peroxidase substrate [0.04% 1, 2-phenylenediamine-
dihydrochloride/OPD/(Sigma-Aldrich Co, St Louis, MO,
USA) in 0.1 M citric acid phosphate buffer (pH 5.0) and
H2O2]. The reaction was terminated by addition of 150 μl
H2SO4 to each well. The absorbance of the wells was
measured at 490 nm with an automatic microplate reader
(Bio-Rad, model 550).
Immunoprecipitation
Thyroid specimens (200 mg) were homogenized in lysis
buffer (1% SDS, 5 mM EDTA, 1% 2-mercaptoethanol,
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samples (700 μg) were incubated 2 h at 4°C under agitation
with anti Akt1 monoclonal antibody, and then, 20 μlo f
Protein G Plus Agarose reagent (Santa Cruz Biotechnology)
was added to each sample. The lysate-beads mixtures
were incubated overnight at 4°C. After centrifugation,
the supernatant was removed, the beads were washed
three times with TBS, and 30 μl of loading buffer was
added. The samples were boiled for 5 min and run on
SDS-PAGE.
Western Blot
The samples (50 μg protein per lane) of cytoplasmic and
nuclear proteins of different types of thyroid lesions or
Akt1 immunoprecipitates were resolved by 8% SDS-PAGE
and electroblotted onto Immobilon-P transfer membranes
(Millipore, Bedford, Massachusetts, USA). The blots were
incubated with the mouse monoclonal anti-Akt1 antibody
or rabbit polyclonal anti-phospho-Akt (Ser473) antibodies
in a 1:1,000 dilution. After being washed three times with
TBST, the membranes were incubated 1 h with goat anti-
mouse or anti-rabbit antibodies conjugated with horseradish
peroxidase which were added in a 1:5,000 dilution. The
membranes were again washed three times with TBST.
Proteins were visualized on X-ray film by enhanced
chemiluminescence method. Gel-Pro® Analyzer software
(Media Cybernetics Inc., USA) was used for densitometry
analysis of protein bands. Intensity of protein bands
quantified by densitometry was used to estimate the ratio
of phospho-Akt1 to total Akt1.
Statistical Analysis
Where appropriate, experimental data are expressed as
mean±SD. Statistical analysis was performed using the
computer program STATISTICA version 9.0 (StatSoft,
Poland). The groups were compared using Mann–Whitney
rank sum test. P value<0.05 was considered statistically
significant.
Results
The results of cytoplasmic Akt1 expression in thyroid
lesions obtained with the ELISA method are shown in
Fig. 1. Akt1 expression level was very variable in each
group of thyroid, i.e., non-neoplastic lesions (nodular
goiters; NN), follicular adenomas (ADE), papillary carci-
nomas (PTC), follicular carcinomas (FTC), and anaplastic
carcinomas (ATC) (Fig. 1a). However, Akt1 expression in
majority of papillary thyroid cancer samples was signifi-
cantly higher than in non-neoplastic lesions (p<0.05).
There were also differences in expression of Akt1 when
benign and malignant lesions groups were compared
(Fig. 1b). There were no statistically significant differences
between adenomas and non-neoplastic lesions and between
different types of cancers (p>0.05). In most cases of
thyroid pathological specimens, the expression of nuclear
Akt1 was very low and we were not able to detect it by
ELISA method (data not shown).
Representative polypeptide patterns of nuclear and
cytoplasmic proteins from thyroid lesions are shown in
Fig. 2a, and the results of Akt1 identification among
proteins of both fractions are shown in Fig. 2b. Akt1 both
in cancer and benign lesions was localized mainly in
cytoplasmic fraction. There were no significant differ-
ences in localization between differentiated cancers
(papillary and follicular carcinomas) and benign lesions
(non-neoplastic lesions and adenoma). In both types of
lesions Akt1 was absent in nucleus or its expression was
very low. However in two of three anaplastic cancer
samples Akt1 was predominantly localized in nucleus
and its expression was five to ten times higher than in
the other samples (Fig. 2b).
Kinase Akt is well-known to be activated by phosphor-
ylation at Ser473. We therefore examined the Akt1
Fig. 1 Analysis of cytoplasmic Akt1 expression in thyroid patholog-
ical specimens by ELISA method. a Akt1 expression in individual
cases of non-neoplastic lesions (NN), adenoma (ADE), follicular
carcinoma (FTC), papillary carcinoma (PTC), and anaplastic carcino-
ma (ATC); b Differences in Akt1 expression between benign and
malignant lesions, error bars represents the mean±SD, p<0.05
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Western blot method using antibodies which recognize Akt
phosphorylation at Ser473. However, the used anti-
phospho-Akt antibodies were non-isoform specific and
recognized not only endogenous level of Akt1 isoform
when phosphorylated at Ser473 but also recognized
Akt2 and Akt3 when they are phosphorylated at the
corresponding residues. Thus, Akt1 was first immuno-
precipitated from cell lysates with monoclonal anti-
Akt1 antibody and then tested with anti-phospho Akt
antibodies (Fig. 3a). The results in most thyroid cancer
samples did not show higher phosphorylation of Akt1
than in benign lesions. On the contrary, the ratio of
phosphorylated Akt1 to total Akt1 was usually lower in
cancers than in non-neoplastic lesions and adenomas
(Fig. 3b)
Discussion
We have analyzed here the expression, phosphorylation,
and cellular localization of Akt1 in human benign and
malignant thyroid lesions, i.e., nodular goiters, adenomas,
papillary carcinomas, follicular carcinomas, and anaplastic
carcinomas.
Kinase Akt is at the crossroads of a number of
intracellular pathways and is a key signaling intermediate
in growth and survival [4]. Overexpression and over-
activation of Akt protein have been detected in aggressive
human gastric cancers as well as breast, prostate, ovarian,
and brain tumors [12]. Increased Akt protein expression
and activity in a subset of human thyroid cancers in
comparison to normal tissue have been also reported earlier.
Ringel et al. [10] demonstrated that thyroid cancers
(especially FTC) are characterized by increase expression
of Akt1 and Akt2 and have increased levels of total Akt
activity in comparison with normal tissue specimens. Akt
has been frequently overexpressed and overactivated also in
papillary carcinoma [13, 14].
Our results showing increased expression of Akt1 in the
most cases of papillary, follicular, and anaplastic thyroid
cancers in comparison with benign lesions are in agreement
Fig. 3 Analysis of Akt1 phosphorylation. a Homogenate proteins of
different thyroid pathological specimens were immunoprecipiteted
with anti-Akt1 antibody and immunoprecipitates were immunobloted
with anti-pAkt (Ser473) antibody or anti-Akt1 antibody. b Intensity of
protein bands was quantified by densitometry and ratio of phospho-
Akt1 to total Akt1 was estimated. Error bars represents the mean±SD
Fig. 2 Analysis of Akt1 expression in cytoplasmic and nuclear
fractions from thyroid pathological specimens; a representative SDS
polyacrylamide gel electrophoresis profiles of cytoplasmic and nuclear
proteins; b Western blotting analysis of Akt1 in cytoplasmic and
nuclear fractions, numbers indicate patient (samples) numbers
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in cancers. Vasco et al. [11] showed that Akt activation and
localization correlate with tumor invasion and oncogene
expression in thyroid cancer. Immunoactive pAkt was
greatest in regions of capsular invasion and was localized
to the nucleus in follicular cancers and the cytoplasm in
papillary cancers, except for invasive regions of papillary
cancers where it was localized in both compartments.
Immunoactive Akt1, but not Akt2 or Akt3, correlated with
pAkt localization [11]. The results of our studies showed
that Akt1 had mainly cytoplasmic localization in most
benign and malignant thyroid pathological specimens.
However, in two of three cases of anaplastic carcinoma,
Akt1 had predominantly nuclear localization. These results
could suggest that nuclear localization is characteristic only
of very aggressive cancers. All cases of follicular carcinoma
used in these studies showed the presence of capsular and
vascular invasions, but there were no widely invasive cases.
The papillary carcinoma cases were classified as stages I
and II (T1–2N0M0) according to TNM staging system.
Our studies revealed the unexpected finding that thyroid
cancers did not have higher phosphorylation of Ser473 of
Akt1 than benign lesions. Moreover, the ratio of phospho-
Akt1 to total Akt1 was even lower in cancer group than in
adenomas and goiters. We do not know the reason of these
discrepancies. But in earlier, mainly immunohistochemical
studies usually, there was no differentiation made between
Akt isoforms and total Akt phosphorylation. Thus, the
activation of other Akt isoforms could increase total Akt
activation. Moreover, Akt phosphorylation in cancers was
compared with normal tissue and not with goiters or
adenomas.
Recent studies have provided evidence for distinct
functions of mammalian Akt isoforms in cancers, particu-
larly with respect to the regulation of cell motility and
metastasis.
Yoeli-Lerner et al. [15] revealed that expression of
activated Akt1 potently blocks the in vitro migration and
invasion of three distinct breast cancer cell lines through
Matrigel. This effect required the kinase activity of Akt1
because an inactive catalytic site mutant did not block
invasion. Similarly, Irie et al. [16] showed that silencing
Akt1 expression enhanced cancer breast cell migration
induced by IGF-1 and EGF and facilitated epithelial to
mesenchymal transition. Hutchison et al. [17] reported that
whereas expression of activated Akt1 in ErbB2 transgenic
mouse mammary tumors enhanced their proliferation, it
also resulted in fewer metastatic lesions compared with
control animals. General Akt activation promotes metasta-
sis in a mouse model of follicular thyroid carcinoma [18].
NPA cells (human papillary thyroid cancer cell line) have
been shown to have Akt1-dependent cell migration.
However, the degree of isoform-specific effects varies
between the different thyroid cancer cell lines [2]. It can
be presumed that Akt1 plays a role in cell proliferation and
survival, but high activity of this isoform is not preferable
for some cancer cells progression. Further studies are
necessary to obtained more information regarding cell-
type dependent isoform expression and specificity in tumor
progression to metastasis.
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